PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma Overview Programmed cell death‐1/ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic approach for advanced urothelial carcinoma, prompting the need for a comparative assessment of their effectiveness and safety in comparison to traditional chemotherapy. To address this, a comprehensive meta-analysis of randomized controlled trials conducted until
Tag: urothelial carcinoma
